生命科学研究2023，Vol.27Issue(6)：506-511,6.DOI:10.16605/j.cnki.1007-7847.2023.02.0121
PD-L1降解途径与肿瘤免疫治疗
PD-L1 Degradation Pathway and Cancer Immunotherapy
摘要
Abstract
Programmed death ligand 1(PD-L1)has emerged as an important target in immune checkpoint blo-ckade therapy for cancer.It is expressed in a variety of cells.Its high expression in tumor cells can enhance programmed death 1(PD-1)inhibitory signals,thus promoting tumor immune escape.In recent years,cancer immunotherapy based on anti-PD-1/PD-L1 antibodies has brought revolutionary changes in cancer treat-ment.However,cancer immunotherapy produces long-lasting treatment effects only in some people with cancer.For most patients,it has short-term or no effects.Studies have found that the degradation of PD-L1 is critical for treatment response to cancer immunotherapy.Herein,the lysosomal and proteasomal pathways of PD-L1 degradation and the interaction of PD-L1 degradation with cancer immunotherapy are reviewed,aiming to provide new ideas for improving response rate and scope in cancer immunotherapy.关键词
程序性死亡受体配体 1(PD-L1)/溶酶体降解途径/蛋白酶体降解途径/肿瘤免疫治疗Key words
programmed death ligand 1(PD-L1)/lysosomal degradation pathway/proteasomal degradation pathway/cancer immunotherapy分类
生物科学引用本文复制引用
李梦,朱成钢..PD-L1降解途径与肿瘤免疫治疗[J].生命科学研究,2023,27(6):506-511,6.基金项目
国家自然科学基金资助项目(82151220) （82151220）
